Navigation Links
Misonix Announces the Purchase of Patents From ProRhythm, Inc.
Date:6/12/2009

FARMINGDALE, N.Y., June 12 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, announced today that it has purchased three patents associated with High Intensity Focused Ultrasound ("HIFU") technology from ProRhythm, Inc. The patents relate to HIFU transducer arrays method of fabrication, ultrasonic lenses, and an intrabody HIFU applicator. The purchase also includes prototypes, transducers and equipment.

Michael A. McManus, Jr., President and CEO said, "We believe the purchase of this patented technology will enable us to continue the internal development of our own HIFU transducer applications. We believe the covered technology will be useful in developing smaller transducers, which may be reusable or disposable. Additionally, we intend to develop the technology for use in a variety of tissue applications. The use of ultrasound is ideal for minimally invasive applications and the technology may provide us entry into other large and growing markets."

Mr. McManus continued, "We presently have a worldwide license from Focus Surgery, Inc., for kidney, liver and breast applications using HIFU. Our plan going forward will involve the development of our own proprietary HIFU technology. We are presently distributing the Sonablate(R)500 in Europe, which uses HIFU for the treatment of prostate cancer. In addition, we are continuing our clinical studies using HIFU for the minimally invasive treatment of kidney tumors. We believe this technology acquisition will further enhance our industry leading position in the development and use of multiple products using HIFU for the treatment of tumors."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Kevin McGrath
    Cameron Associates, Inc.
    212-245-4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
2. Misonix Announces Participation in Annual Diabetic Foot Global Conference
3. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
4. Misonix Announces New HIFU Distribution Agreement For Portugal
5. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
6. Misonix Announces New Distribution Agreement for Portugal
7. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
8. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
9. Misonix Announces New Sales Agency Agreement for Eastern Europe
10. Misonix Announces New Distribution Agreement for Israel
11. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... social media management, corporate communications, SEO and cause marketing, is opening an office ... New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... host a diverse symposium on “Doping in Sport: How the Culture Might ... Richter & Hampton LLP. The symposium will be held at Pepperdine University in ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... ... February 23, 2017 , ... Current ... will soon begin franchising throughout the U.S. starting this spring. Current Meditation focuses ... practice of meditation mainstream. Current Meditation will be the first meditation concept in ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center ... Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present ... spectrum disorder (ASD) to see films in an environment that accommodates their unique ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017 AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... it will release fourth quarter and yearly financial ... 2017. AcelRx management will host an investment-community conference ... Pacific Time) on March 2 nd 2017 ...
(Date:2/23/2017)... -- ... Research and Markets has announced the addition of the "Global Antifungal ... to their offering. The Global Antifungal Drugs Market is ... decade to reach approximately $12.8 billion by 2025. ... given segments on global as well as regional levels presented in the ...
(Date:2/23/2017)... New York , February 23, 2017 ... Cardiac Holter Monitor Market are GE Healthcare, Koninklijke Philips ... of about 48% in the global market in 2015. ... the two key factors assessed to be aiding these ... Market Research states that the players in the global ...
Breaking Medicine Technology: